Division of Medical Oncology, British Columbia Cancer Agency Vancouver Cancer Centre, Vancouver BC V5Z 4E6, Canada.
Semin Oncol. 2013 Aug;40(4):499-510. doi: 10.1053/j.seminoncol.2013.05.011.
The introduction of targeted therapy has changed the landscape of metastatic renal cell carcinoma (mRCC) but has also brought challenges. One such challenge of treating this chronic disease is long-term therapy, which produces ongoing toxicity. Knowledge of the spectrum of toxicity from targeted therapy and appropriate and timely intervention is required to maintain adequate dosing required for optimal outcome. This article addresses some of the major toxicities of newer agents in RCC and discusses management strategies.
靶向治疗的引入改变了转移性肾细胞癌（mRCC）的治疗格局，但也带来了挑战。治疗这种慢性疾病的一个挑战是长期治疗，这会产生持续的毒性。为了达到最佳疗效，需要了解靶向治疗的毒性谱，并进行适当和及时的干预。本文讨论了 RCC 中一些新型药物的主要毒性，并探讨了管理策略。
